Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WBRT and SRS with or without Temozolomide or Erlotinib in NSCLC with Brain Metastases
NCT00268684Phase 3Unknown
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of temozolomide, erlotinib in non-small cell lung cancer (NSCLC), brain metastasis (BM), sponsored by Tel Aviv Sourasky Medical Center. Status: unknown.
02
Drugs
temozolomideerlotinib
03
Conditions
non-small cell lung cancer (NSCLC)brain metastasis (BM)
Beyond the preview
Go deeper on NCT00268684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00268684.